Promising Overall Survival And Progression-free Survival With VARGATEF(TM) (BIBF 1120) For Advanced, Relapsed Non-small Cell Lung Cancer
May 15th 2008Drug InformationLung Cancer
Monotherapy treatment with the triple angiokinase inhibitor1 BIBF 1120 (planned tradename VARGATEF?) offers promising efficacy and is well tolerated in patients with advanced, relapsed non-small cell lung cancer (NSCLC), according to results from a phase II study in patients with lung cancer2.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
